Tirzepatide pen use on TikTok: what the hype misses

What did @pinaymumsinaustralia actually say?

This video is a hands-on injection tutorial, not a health claim. The creator walks through loading what appears to be a compounded peptide pen, priming it, dialing to "six units," and injecting subcutaneously. She says upfront: "this is not a medical advice, I'm only sharing based on experience." That disclaimer is good faith, but it does not neutralize the real risks of what follows.

The transcript is partly in Tagalog and partly in English, making it hard to catch every detail, but the core instruction is clear: dial to six, prime the pen, pinch skin, inject. She also mentions "bronch nippies" and needle changes, which suggests she understands basic pen hygiene. What she does not mention is what substance is in the pen, what concentration it is, or what medical supervision, if any, is behind these six units.

Does the science back this up?

The injection technique she demonstrates, subcutaneous administration with a short needle, is textbook correct for GLP-1 receptor agonists and peptide-based compounds. The clinical evidence is not in dispute there. What is disputed is everything surrounding the technique: dose, substance identity, and who is doing the dosing math.

Tirzepatide, the drug referenced in her hashtags, is approved by the TGA in Australia as Mounjaro. It is dosed in fixed increments (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) using factory-calibrated pens, not "units" dialed on a manual syringe-style pen. When the creator says "six units," that phrase has no standardized meaning outside insulin. For compounded peptides, "units" depends entirely on the reconstitution math done by whoever prepared the vial or pen. Wilding et al. (2021, New England Journal of Medicine) established tirzepatide's clinical dose range in the SURMOUNT-1 trial under strict medical protocol. None of that protocol involves self-dialing units on an unbranded pen.

• Subcutaneous injection site rotation and technique: well-supported (Davies et al., 2016, Diabetes Care)
• Self-titration without medical guidance: not supported by any approved prescribing protocol
• "Units" as a dose measurement for tirzepatide or semaglutide: not a recognized clinical unit for these drugs

What did they get wrong (or right)?

Credit where it is due: she primes the pen before injecting. That step matters. Air bubbles in a peptide pen waste medication and can affect dose accuracy. She also mentions changing needles, which is correct infection-control practice. These are the things she got right, and they are genuinely useful for someone who is already under medical supervision and needs a visual refresher.

What she got wrong, or at least left dangerously incomplete, is the dose framing. Saying "go to six" without explaining what concentration the pen contains, what body weight the dose is calibrated to, or what clinical guidance underpins that number is not educational content. It is a number floating in a vacuum. For a GLP-1 or dual GIP/GLP-1 compound, dosing errors do not just cause discomfort. Nausea, vomiting, hypoglycemia in diabetic patients, and pancreatitis are documented adverse effects at inappropriate doses (Drucker, 2022, Cell Metabolism). The "do your research" instruction does not substitute for a prescriber doing the math.

The use of the word "peptide" as a category is also worth flagging. It is doing a lot of vague work here. Not all peptides are equivalent, not all compounded versions are equivalent to approved drugs, and the TGA has specific rules about compounded tirzepatide that many informal pen-sharing communities ignore.

What should you actually know?

If you are using a GLP-1 or dual agonist in Australia, the TGA-approved pathway exists for a reason. Compounded versions may be legally obtained through authorized compounding pharmacies with a valid prescription, but the concentration, sterility, and dose accuracy of compounded products are not held to the same manufacturing standards as approved drugs. The TGA has issued warnings on this explicitly.

The phrase "units" on a manual peptide pen is not a universal measurement. It means nothing without knowing the concentration of the solution in the pen. Two people both injecting "six units" from different pens could be injecting very different amounts of active compound. That is not a minor detail. It is the difference between a therapeutic dose and an overdose.

If you are learning injection technique, a video like this can be a useful visual supplement. But it cannot replace a pharmacist showing you your specific pen and your specific dose. In Australia, PBS-listed and private-prescription GLP-1 medications come with patient education resources. Use them.